SEARCH

SEARCH BY CITATION

References

  • 1
    Bertoletti, A. and Ferrari, C., Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2011. 61: 17541764.
  • 2
    Schirmbeck, R., Wild, J. and Reimann, J., Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur. J. Immunol. 1998. 28: 41494161.
  • 3
    Basler, M., Youhnovski, N., Van Den, B. M., Przybylski, M. and Groettrup, M., Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J. Immunol. 2004. 173: 39253934.
  • 4
    Tenzer, S., Wee, E., Burgevin, A., Stewart-Jones, G., Friis, L., Lamberth, K., Chang, C. H. et al., Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat. Immunol. 2009. 10: 636646.
  • 5
    Cockburn, I. A., Tse, S. W., Radtke, A. J., Srinivasan, P., Chen, Y. C., Sinnis, P. and Zavala, F., Dendritic cells and hepatocytes use distinct pathways to process protective antigen from plasmodium in vivo. PLoS. Pathog. 2011. 7: e1001318.
  • 6
    Holz, L. E., Warren, A., Le Couteur, D. G., Bowen, D. G. and Bertolino, P., CD8+ T cell tolerance following antigen recognition on hepatocytes. J. Autoimmun. 2010. 34: 1522.
  • 7
    Crispe, I. N., Liver antigen-presenting cells. J. Hepatol. 2011. 54: 357365.
  • 8
    Heermann, K. H., Goldmann, U., Schwartz, W., Seyffarth, T., Baumgarten, H. and Gerlich, W. H., Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 1984. 52: 396402.
  • 9
    Ganem, D. and Prince, A. M., Hepatitis B virus infection—natural history and clinical consequences. N. Engl. J. Med. 2004. 350: 11181129.
  • 10
    Kondo, Y., Ninomiya, M., Kakazu, E., Kimura, O. and Shimosegawa, T., Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection. ISRN. Gastroenterol. 2013. 2013: 935295.
  • 11
    Janowicz, Z. A., Melber, K., Merckelbach, A., Jacobs, E., Harford, N., Comberbach, M. and Hollenberg, C. P., Simultaneous expression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha. Yeast 1991. 7: 431443.
  • 12
    Schirmbeck, R., Melber, K., Mertens, T. and Reimann, J., Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 1994. 68: 14181425.
  • 13
    Schirmbeck, R., Melber, K. and Reimann, J., Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur. J. Immunol. 1995. 25: 10631070.
  • 14
    Stober, D., Trobonjaca, Z., Reimann, J. and Schirmbeck, R., Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells. Eur. J. Immunol. 2002. 32: 10991108.
  • 15
    Cresswell, P., Ackerman, A. L., Giodini, A., Peaper, D. R. and Wearsch, P. A., Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol. Rev. 2005. 207: 145157.
  • 16
    Gurunathan, S., Klinman, D. M. and Seder, R. A., DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 2000. 18: 927974.
  • 17
    Duewell, P., Kisser, U., Heckelsmiller, K., Hoves, S., Stoitzner, P., Koernig, S., Morelli, A. B. et al., ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J. Immunol. 2011. 187: 5563.
  • 18
    Kurts, C., Robinson, B. W. and Knolle, P. A., Cross-priming in health and disease. Nat. Rev. Immunol. 2010. 10: 403414.
  • 19
    Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J. et al., Relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 1994. 153: 55865592.
  • 20
    Price, D. A., Brenchley, J. M., Ruff, L. E., Betts, M. R., Hill, B. J., Roederer, M., Koup, R. A. et al., Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J. Exp. Med. 2005. 202: 13491361.
  • 21
    Willis, R. A., Kappler, J. W. and Marrack, P. C., CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc. Natl. Acad. Sci. USA 2006. 103: 1206312068.
  • 22
    Wu, Y. U., Xia, L., Zhang, M. and Zhao, X., Immunodominance analysis through interactions of CD8+ T cells and DCs in lymph nodes. Math. Biosci. 2010. 225: 5358.
  • 23
    Akram, A. and Inman, R. D., Immunodominance: a pivotal principle in host response to viral infections. Clin. Immunol. 2012. 143: 99115.
  • 24
    Ferrari, C., Bertoletti, A., Penna, A., Cavalli, A., Valli, A., Missale, G., Pilli, M., et al., Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J. Clin. Invest. 1991. 88: 214222.
  • 25
    Schirmbeck, R., Stober, D., El Kholy, S., Riedl, P. and Reimann, J., The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes. J. Immunol. 2002. 168: 62536262.
  • 26
    Riedl, P., Wieland, A., Lamberth, K., Buus, S., Lemonnier, F., Reifenberg, K., Reimann, J. et al., Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential. J. Immunol. 2009. 183: 370380.
  • 27
    Wieland, A., Riedl, P., Reimann, J. and Schirmbeck, R., Silencing an immunodominant epitope of hepatitis B surface antigen reveals an alternative repertoire of CD8 T cell epitopes of this viral antigen. Vaccine 2009. 28: 114119.
  • 28
    Halverscheid, L., Mannes, N. K., Weth, R., Kleinschmidt, M., Schultz, U., Reifenberg, K., Schirmbeck, R. et al., Transgenic mice replicating hepatitis B virus but lacking expression of the major HBsAg. J. Med. Virol. 2008. 80: 583590.
  • 29
    Rammensee, H. G., Friede, T. and Stevanoviic, S., MHC ligands and peptide motifs: first listing. Immunogenetics 1995. 41: 178228.
  • 30
    Schirmbeck, R., Dikopoulos, N., Kwissa, M., Leithauser, F., Lamberth, K., Buus, S., Melber, K. et al., Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur. J. Immunol. 2003. 33: 33423352.
  • 31
    Lovgren, B. K., Morein, B. and Osterhaus, A. D., ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines. 2011. 10: 401403.
  • 32
    Ljunggren, H. G., Stam, N. J., Ohlen, C., Neefjes, J. J., Hoglund, P., Heemels, M. T., Bastin, J. et al., Empty MHC class I molecules come out in the cold. Nature 1990. 346: 476480.
  • 33
    Watanabe, T., Bertoletti, A. and Tanoto, T. A., PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J. Viral Hepat. 2010. 17: 453458.
  • 34
    Harndahl, M., Rasmussen, M., Roder, G., Dalgaard, P. I., Sorensen, M., Nielsen, M. and Buus, S., Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur. J. Immunol. 2012. 42: 14051416.
  • 35
    Stryhn, A., Pedersen, L. O., Romme, T., Olsen, A. C., Nissen, M. H., Thorpe, C. J. and Buus, S., pH dependence of MHC class I-restricted peptide presentation. J. Immunol. 1996. 156: 41914197.
  • 36
    Vogt, W., Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic. Biol. Med. 1995. 18: 93105.
  • 37
    Wieland, A., Denzel, M., Schmidt, E., Kochanek, S., Kreppel, F., Reimann, J. and Schirmbeck, R., Recombinant complexes of antigen with stress proteins are potent CD8 T-cell-stimulating immunogens. J. Mol. Med. 2008. 86: 10671079.
  • 38
    Ebrahimkhani, M. R., Mohar, I. and Crispe, I. N., Cross-presentation of antigen by diverse subsets of murine liver cells. Hepatology 2011. 54: 13791387.
  • 39
    Kakimi, K., Isogawa, M., Chung, J., Sette, A. and Chisari, F. V., Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 2002. 76: 86098620.
  • 40
    Pol, S., Nalpas, B., Driss, F., Michel, M. L., Tiollais, P., Denis, J. and Brecho, C., Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 2001. 34: 917921.
  • 41
    Jung, M. C., Gruner, N., Zachoval, R., Schraut, W., Gerlach, T., Diepolder, H., Schirren, C. A. et al., Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002. 20: 35983612.
  • 42
    Bienzle, U., Gunther, M., Neuhaus, R., Vandepapeliere, P., Vollmar, J., Lun, A. and Neuhaus, P., Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003. 38: 811819.
  • 43
    Vandepapeliere, P., Lau, G. K., Leroux-Roels, G., Horsmans, Y., Gane, E., Tawandee, T., Merican, M. I. et al., Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007. 25: 85858597.
  • 44
    Locarnini, S. and Bowden, S., Hepatitis B surface antigen quantification: Not what it seems on the surface. Hepatology 2012. 56: 411414.
  • 45
    Chisari, F. V., Klopchin, K., Moriyama, T., Pasquinelli, C., Dunsford, H. A., Sell, S., Pinkert, C. A. et al., Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989. 59: 11451156.
  • 46
    Wahl, C., Bochtler, P., Schirmbeck, R. and Reimann, J., Type I IFN-producing CD4 Valpha14i NKT cells facilitate priming of IL-10-producing CD8 T cells by hepatocytes. J. Immunol. 2007. 178: 20832093.